An open-label Phase 2 clinical trial will test the safety and efficacy of IRX-2, an experimental immunology-based cancer therapy, in combination with Keytruda (pembrolizumab) and chemotherapy. The study is enrolling adults with triple-negative breast cancer (TNBC) — cancers not driven by the hormones progesterone or estrogen, or by the protein HER2 — according to the therapy’s developer, Brooklyn ImmunoTherapeutics. Already underway at the Providence Cancer Institute, in Portland, Ore., the trial (NCT04373031) is expected to enroll…
You must be logged in to read/download the full post.
The post Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC appeared first on BioNewsFeeds.